NCT04524403: A trial that was reported late by Corcept Therapeutics
This trial has reported, although it was 297 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04524403 |
|---|---|
| Title | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia Taking Antipsychotic Medications (GRATITUDE II) |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 9, 2020 |
| Completion date | July 29, 2022 |
| Required reporting date | July 29, 2023, midnight |
| Actual reporting date | May 21, 2024 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | 297 |